

SEP 7 2004 2:37PM

AVENTIS US PAT DEPT

NO. 7318 P. 1

DT07 Rec'd PCT/PTO 07 SEP 2004

FAX TRANSMITTAL
TO THE UNITED STATES PATENT OFFICEApplicants Docket Number:
USCA2332 US CNTApplicants:
BRYANT, et al.Serial No.
10/758,893Filing Date:
January 15, 2004Title of Invention:
Novel Compounds and Compositions as Protease Inhibitors

CERTIFICATE OF TRANSMISSION

I hereby certify that this correspondence is being transmitted via
facsimile to the Commissioner for Patents, P.O. Box 1450, Alexandria,
VA 22313-1450, at 703-746-9195, on

Date of Deposit: September 7, 2004

Printed Name of Person Signing Certificate: Paul Irvine

Signature: 

Total Number of Pages Sent: 4

Attorney: George Wang

Group Art Unit: 1624

Examiner:

TO:

Commissioner for Patents
P. O. Box 1450
Alexandria, VA 22313-1450

Please acknowledge receipt of the below-listed documents for the above Application by returning this sheet, signed and dated, by return telefax to (908) 231-2626. If any fees are required, please charge our deposit account (18-1982) in the name of Aventis Pharmaceuticals Inc.

- | | |
|--|---|
| <input type="checkbox"/> Amendment, 37 CFR _____ | <input type="checkbox"/> Fee Transmittal |
| <input type="checkbox"/> Charge deposit account, in duplicate | <input type="checkbox"/> Petition under 37 CFR _____ |
| <input type="checkbox"/> Extension of Time Petition | <input checked="" type="checkbox"/> Other <u>REQUEST FOR CORRECTED FILING RECEIPT</u> |
| <input type="checkbox"/> Issue Fee Transmittal & Advance Order | <input checked="" type="checkbox"/> Other <u>Copy of Filing Receipt</u> |
| <input type="checkbox"/> Maintenance Fee Transmittal | |

Aventis Pharmaceuticals Inc., Route 202-206, P.O. Box 6800, Bridgewater, New Jersey 08807, U.S.A. www.aventis.com
NOTICE: The documents accompanying this telecopy transmission are intended only for the use of the individual or entity named above. If you have received this telecopy in error, please immediately notify the sender by telephone to arrange for the return of the original documents.

Aventis Pharmaceuticals Inc. template (March 2001)

PATENT**IN THE UNITED STATES PATENT AND TRADEMARK OFFICE**

In re Application of
BRYANT, et al.

Examiner:

Art Unit: 1624


Application No.: 10/758,893

Filed: **January 15, 2004**

Title: **Novel Compounds and Compositions as
Protease Inhibitors**

I hereby certify that this correspondence is being
transmitted via facsimile to the Commissioner for
Patents, P. O. Box 1450, Alexandria, VA 22313-1450,
at (703) 746-9195, on

7 September 2004
Date of Transmission

Signature 

REQUEST FOR CORRECTED FILING RECEIPT


Commissioner of Patents
P. O. Box 1450
Alexandria, VA 22313-1450

Attached is a copy of the official Filing Receipt from the Patent and Trademark Office in the
above-identified application, for which issuance of a corrected filing receipt is respectfully requested.

There is an error in Domestic Priority data as claimed by the Applicant. A third line needs to
be added stating, "and claims benefit of 60/124,420 filed 03/15/1999"

The correction is not due to any error by Applicants and no fee is due.

Respectfully submitted,


George G. Wang, Reg. No. 41,419
Attorney for Applicant


Aventis Pharmaceuticals Inc.
Patent Department
Route #202-206 / P.O. Box 6800
Bridgewater, NJ 08807-0800
Telephone (908) 231-2843
Telefax (908) 231-2626

Aventis Docket No. USCA2332 US CNT

BEST AVAILABLE COPY



UNITED STATES PATENT AND TRADEMARK OFFICE


 UNITED STATES DEPARTMENT OF COMMERCE
 United States Patent and Trademark Office
 Address: COMMISSIONER FOR PATENTS
 P.O. Box 1450
 Alexandria, Virginia 22313-1450
 www.uspto.gov

APPL NO.	FILING OR 371 (c) DATE	ART UNIT	FIL FEE REC'D	ATTY. DOCKET NO.	DRAWINGS	TOT CLMS	IND CLMS
10/758,893	01/15/2004	1624	1064	015058-003011US	19	22	6

USCA2332-US-CNT

CONFIRMATION NO. 6980

George Wang
 Aventis Pharmaceuticals, Inc.
 300 Somerset Corporate Blvd.
 Route 202-206, Mail Code D303A
 Bridgewater, NJ 08807

FILING RECEIPT



OC000000012403497

COMPUTER ENTERED

Receipt is acknowledged of this regular Patent App
 notified as to the results of the examination. Be sure to
 NAME OF APPLICANT, and TITLE OF INVENTION
 check or draft are subject to collection. Please verify
 error is noted on this Filing Receipt, please write
 Receipt Corrections, facsimile number 703-746-911
 changes noted thereon. If you received a "Notice to
 any corrections to this Filing Receipt with your reply
 to the Notice, the USPTO will generate another Filing
 appropriate).

Applicant(s)

Clifford M. Bryant, Millbrae, CA;
 Barry A. Bunin, San Bruno, CA;
 Erica A. Kraynack, Oakland, CA;
 John W. Patterson, Mountain View, CA

Assignment For Published Patent Application

Axys Pharmaceuticals, Inc., So. San Francisco

Domestic Priority data as claimed by applicant

This application is a CON of 10/205,601
 which is a DIV of 09/526,090 03/15/2001

Foreign Applications

If Required, Foreign Filing License Granted: 04/20/2004

Projected Publication Date: 07/29/2004

Non-Publication Request: No

Early Publication Request: No

Prepare 1 file
 request for
 corrected filing receipt
 add

claim benefit
 of 60/124,420

filed 3/15/1999

To Priority data
 Section

USCA2332

US-CNT

AVAILABLE COPY

Title

Novel compounds and compositions as protease inhibitors

Preliminary Class

544

**LICENSE FOR FOREIGN FILING UNDER
Title 35, United States Code, Section 184
Title 37, Code of Federal Regulations, 5.11 & 5.15**

GRANTED

The applicant has been granted a license under 35 U.S.C. 184, if the phrase "IF REQUIRED, FOREIGN FILING LICENSE GRANTED" followed by a date appears on this form. Such licenses are issued in all applications where the conditions for issuance of a license have been met, regardless of whether or not a license may be required as set forth in 37 CFR 5.15. The scope and limitations of this license are set forth in 37 CFR 5.15(a) unless an earlier license has been issued under 37 CFR 5.15(b). The license is subject to revocation upon written notification. The date indicated is the effective date of the license, unless an earlier license of similar scope has been granted under 37 CFR 5.13 or 5.14.

This license is to be retained by the licensee and may be used at any time on or after the effective date thereof unless it is revoked. This license is automatically transferred to any related applications(s) filed under 37 CFR 1.53(d). This license is not retroactive.

The grant of a license does not in any way lessen the responsibility of a licensee for the security of the subject matter as imposed by any Government contract or the provisions of existing laws relating to espionage and the national security or the export of technical data. Licensees should apprise themselves of current regulations especially with respect to certain countries, of other agencies, particularly the Office of Defense Trade Controls, Department of State (with respect to Arms, Munitions and Implements of War (22 CFR 121-128)); the Office of Export Administration, Department of Commerce (15 CFR 370.10 (j)); the Office of Foreign Assets Control, Department of Treasury (31 CFR Parts 500+) and the Department of Energy.

NOT GRANTED

No license under 35 U.S.C. 184 has been granted at this time, if the phrase "IF REQUIRED, FOREIGN FILING LICENSE GRANTED" DOES NOT appear on this form. Applicant may still petition for a license under 37 CFR 5.12, if a license is desired before the expiration of 6 months from the filing date of the application. If 6 months has lapsed from the filing date of this application and the licensee has not received any indication of a secrecy order under 35 U.S.C. 181, the licensee may foreign file the application pursuant to 37 CFR 5.15(b).